Compass Pathways PLC (5Y6.BE)

Confronta

4.1400

+0.1400

+(3.50%)

Alla chiusura: January 31 at 9:52:09 PM GMT+1

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

LONDON & NEW YORK, January 21, 2025--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced the appointment of Steve Levine, M.D., as Chief Patient Officer, effective immediately. In this newly developed executive team role, Dr. Levine will be responsible for ensuring that patient-centric strategies are embedded across the organization and that treatments and initiatives developed by

Business Wire 11 days ago

CMPS
Compass Pathways Announces Pricing of Underwritten Offering

LONDON & NEW YORK, January 10, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of an underwritten offering of 24,014,728 American Depositary Shares ("ADSs") and in lieu of ADS, to certain institutional investors, pre-funded warrants to purchase up to 11,044,720 ADSs. Each ADS and pre-funded warrant shall be accompanied by a warrant ("ADS Warrant") to purchase one

Business Wire 22 days ago

CMPS
Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

LONDON, December 18, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today its common stock will be added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 23, 2024.

Business Wire last month

CMPS
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Don't jump in without doing some research first.

Motley Fool 2 months ago

CMPS
Compass Pathways to Participate in December Investor Conferences

LONDON & NEW YORK, November 25, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of the executive management team will participate in the following investor conferences in addition to hosting investor meetings:

Business Wire 2 months ago

CMPS
COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Key Insights Institutions' substantial holdings in COMPASS Pathways implies that they have significant influence over...

Simply Wall St. 2 months ago

CMPS
Compass Pathways to participate in Stifel 2024 Healthcare Conference

LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days

GlobeNewswire 2 months ago

CMPS
Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways (CMPS) announced yesterday morning with earnings that as a result of changing timelines for its Phase 3 trials, it will be reducing its workforce by approximately 30%, including eliminating some senior management positions, “to further focus the organization and its capital resources on successfully delivering the COMP360 program.” The company’s non-COMP360 preclinical efforts will be stopped and it is “exploring a potential externalization” for its digital health tools. Publish

TipRanks 2 months ago

CMPS
Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Despite workforce reductions and trial delays, Compass Pathways PLC (CMPS) maintains a strong cash position and focuses on commercializing COMP360 for treatment-resistant depression.

GuruFocus.com 2 months ago

CMPS
Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

CMPS earnings call for the period ending September 30, 2024.

Motley Fool 2 months ago

CMPS
Compass delays anticipated psilocybin readout, cuts staff

The company’s moves come after the FDA seemed to place a new hurdle in the path of psychedelic treatments for mental disorders.

BioPharma Dive 3 months ago

CMPS
Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

LONDON & NEW YORK, October 31, 2024--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

Business Wire 3 months ago

CMPS
Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

LONDON, October 24, 2024--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

Business Wire 3 months ago

CMPS
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

LONDON & NEW YORK, September 23, 2024--Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, announced today that executives from the management team will be participating in a fireside chat at the Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit on September 26, 2024 at 1:20pm ET.

Business Wire 4 months ago

CMPS
Compass Pathways to participate in three investor conferences in September

LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetingsH. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:

GlobeNewswire 5 months ago

CMPS
Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

Despite a rocky start in August, investor sentiment has remained resilient, with the S&P 500 rallying nearly 9% since its August 5th low. This upward momentum has been driven by a series of positive economic data releases, including better-than-expected initial jobless claims and strong retail sales figures. Wall Street also reacted favorably to Federal Reserve Chair Jerome Powell’s comments on Friday, signaling that the Fed is prepared to cut interest rates as the labor market softens and infla

TipRanks 5 months ago

RCKT

RCKTW

CMPS
More promise for psilocybin in depression but safety remains a concern

Psilocybin showed positive signs as a potential treatment for neurological conditions, but safety concerns need to be addressed.

Clinical Trials Arena 5 months ago

GLDAF

CMPS
COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

LONDON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Canaccord Genuity 44th Annual Growth Conference: presentation at 4:30pm ET on August 13, 2024 and host investor meetings. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A rep

GlobeNewswire 5 months ago

CMPS
Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

CMPS earnings call for the period ending June 30, 2024.

Motley Fool 5 months ago

CMPS
Compass Pathways announces second quarter 2024 financial results and business highlights

Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million Conference call August 1 at 8:00 am ET (1:00 pm UK) LONDON and NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation

GlobeNewswire 5 months ago

CMPS

Panoramica delle performance

Rendimento	5Y6.BE	MSCI WORLD
YTD	+8.95%	+3.16%
1 anno/i	-60.57%	+19.69%
3 anno/i	-70.32%	+25.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Compass Pathways PLC (5Y6.BE)

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

Compass Pathways Announces Pricing of Underwritten Offering

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

Compass Pathways to Participate in December Investor Conferences

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Compass delays anticipated psilocybin readout, cuts staff

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to participate in three investor conferences in September

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

More promise for psilocybin in depression but safety remains a concern

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

Compass Pathways announces second quarter 2024 financial results and business highlights

Panoramica delle performance